Karyn Foster

Karyn Foster

Auto-generated profile, based on publicly available information

Karyn Foster

Mater Research Institute The University of Queensland, South Brisbane, Queensland, Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2024 in Palliative Medicine
Verified
Journal Article
Closed access
KFKaryn Foster
Karyn Foster
GMGeoff Mitchell
Geoff Mitchell
EREvan Richard
Evan Richard
KSKathryn J Steadman
Kathryn J Steadman
HSHugh Senior
Hugh Senior
JHJanet Hardy
Janet Hardy
Background: Xerostomia is a common and difficult symptom experienced by patients with cancer. Pilocarpine is a cholinergic agent that stimulates salivation. Aim: To assess the feasibility of conducting a N-of-1 trial to determine the efficacy of pilocarpine orally dissolving tablets in patients with xerostomia. Design: Double-blind, crossover, placebo-controlled N-of-1 trials of 5 mg pilocarpine tablets vs placebo. Each trial consisted of three 6-day cycles containing pilocarpine (3 days) and placebo (3 days) in random order. Setting/participants: Participants with advanced cancer and xerostomia (scoring >3 on an 11-point numerical rating scale) from any cause, were recruited from an inpatient and outpatient palliative care unit in Brisbane, Australia. Results: Eighteen people were recruited in 17 months. Nine withdrew, seven before or during the first 4 days. Three withdrew due to unacceptable side effects. Two participants met the definition of response (⩾2 point reduction in mean scores active vs placebo cycles). When assessing individual cycles, 15 out of 27 cycles (56%) met the definition of response. More people reported at least one mild episode during pilocarpine than placebo of nausea (6 vs 3), vomiting (3 vs 0) and sweating (3 vs 2). About 48% of adverse event classifications were reported in placebo cycles only. Conclusion: Recruitment to an N-of-1 trial for xerostomia is feasible but attrition was high (50%). Early dropout may have been due to the trial length, complexity, appropriateness or number of questionnaires. Adverse events were generally mild. Two of 10 participants were considered to have benefited from pilocarpine warranting ongoing treatment.

1 September 2017 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
PVPetra Vayne-Bossert
Petra Vayne-Bossert
JHJanet Hardy
Janet Hardy
HSHelen Skerman
Helen Skerman
PYPatsy Yates
Patsy Yates
KSKaryn Sullivan
Karyn Sullivan
PGPhillip Good
Phillip Good

3 May 2017 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
PVP. Vayne-Bossert
P. Vayne-Bossert
ERE. Richard
E. Richard
PGPhillip Good
Phillip Good
KSK. Sullivan
K. Sullivan
JHJ.R. Hardy
J.R. Hardy

23 April 2021 in Progress in Palliative Care
Verified
Journal Article
Closed access
BGBen Gunawan
Ben Gunawan
KFKaryn Foster
Karyn Foster
JHJanet Hardy
Janet Hardy
PGPhillip Good
Phillip Good
Malignant ureteric obstruction (MUO) is a life-threatening complication of advanced cancer associated with short survival. Percutaneous nephrostomy (PCN) is a commonly employed technique to decompr...

8 January 2022 in BMJ Supportive & Palliative Care
Verified
Journal Article
Closed access
PDF file
WBWan Fadzrul Izuan Bin Wan Bahrum
Wan Fadzrul Izuan Bin Wan Bahrum
JHJanet Hardy
Janet Hardy
KFKaryn Foster
Karyn Foster
PGPhillip Good
Phillip Good
Objectives Malignant bowel obstruction (MBO) is a common, challenging condition in advanced cancer. Oral water-soluble contrast medium (Gastrografin) has been used in the management of MBO without quality studies of its effectiveness and safety. The purpose of this study was to evaluate the feasibility, effectiveness and adverse effects of Gastrografin in patients with MBO and to assess feasibility of the study protocol. Methods A prospective, interventional, single-arm, open label study of Gastrografin across two centres. Patients with unresolved inoperable MBO after 24 hours of conservative medical management were given a single dose of 100 mL of oral Gastrografin. Results Over 33 months, 69 individual patients were screened. Of the 20 recruited, 17 completed study assessments (85%). MBO resolved in 10 of 17 patients (59%). Gastrografin passed through to the rectum in 14 patients (78%). The most common adverse effects were diarrhoea, vomiting, nausea and abdominal pain. Conclusions Patient recruitment took longer than anticipated, but the study protocol is feasible. Gastrografin was found to be a relatively effective option for the treatment of MBO. An adeqautely powered randomised controlled trial is needed to formally assess the efficacy and safety of Gastrografin© in MBO.

18 December 2025 in BMJ Supportive & Palliative Care
Verified
Journal Article
Closed access
JHJanet Hardy
Janet Hardy
Ristan GreerRistan Greer
Ristan Greer
KFKaryn Foster
Karyn Foster
NONiara Oliveira
Niara Oliveira
PGPhillip Good
Phillip Good
AEAdam D Ewing
Adam D Ewing
Objectives: Men with castrate-resistant prostate cancer (CRPC) suffer from symptoms related to both their disease and its treatment with marked variation between individuals with respect to symptom expression. This study aimed to determine whether genetic variation in cytokine expression is associated with symptom severity. Methods: An exploratory prospective, longitudinal consecutive patient cohort study was undertaken across two Queensland sites. Patient characteristics including tumour burden and current treatment were collected at baseline. Symptom severity was assessed 3–4 weekly for up to 6 assessments, with blood taken for genetic analysis once only during the study. Cytokine gene variants of each participant were assessed using a panel of single nucleotide polymorphisms (SNPs) most described in the literature. Results: Of the 66 participants, 27/66 (41%) had a low, and 39/66 (59%) a high tumour burden. Symptom severity was not related to tumour burden or patient characteristics. Of the 142 SNPs analysed from 62 participants, 15 SNPs from 7 genes were significantly associated with symptom severity. After Benjamini-Hochberg adjustment, SNPs rs2069772 from Interleukin-2 (IL2) and rs230494 from Nuclear Factor kappa-light-chain-enhancer of activated B cells (NFKb) remained significant. Conclusion: Although multiple factors can influence symptom severity, genetic variation may play a part. The early identification of men likely to develop severe symptoms during the course of their prostate cancer could theoretically enable symptoms to be managed more aggressively from an early stage. These preliminary findings need to be replicated in a larger cohort of men with CRPC.